Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Exxon, Parexel, RadioShack, VeriFone, Vertex: U.S. Equity Movers

Shares of the following companies had unusual moves in U.S. trading. Stock symbols are in parentheses, and prices are as of 4 p.m. in New York.

Align Technology Inc. (ALGN US) fell 7.2 percent, the most since Aug. 8, to $23.56. The maker of a teeth-straightening product forecast first-quarter profit excluding some items of no more 21 cents a share, below the average analyst estimate of 22 cents in a Bloomberg survey.

Archer-Daniels-Midland Co. (ADM US) declined 3.6 percent, the most since Nov. 9, to $28.63. The world’s largest grain processor posted a second-quarter profit that missed analysts’ estimates after oilseed earnings fell and corn costs rose.

Avery Dennison Corp. (AVY US) 5.4 percent, the most since Oct. 19, to $27.15. The world’s largest label maker forecast 2012 earnings excluding some items of $2.15 a share at most. That trailed the average analyst estimate of $2.27 in a Bloomberg survey.

Edwards Lifesciences Corp. (EW US) rose 5.6 percent to $82.67 for the second-biggest increase in the S&P 500. Elderly patients getting the company’s Sapien heart valve implanted through the ribs as part of an expanded access program reaped more benefit than those observed in the initial trials, a study found.

Exxon Mobil Corp. (XOM US) fell the most in the Dow Jones Industrial Average, sinking 2.1 percent to $83.74. The world’s largest energy company by market value reported fourth-quarter sales that fell short of analysts’ estimates and oil production slumped on five continents.

Mattel Inc. (MAT US) gained 5 percent to $31, the highest intraday price since December 1998. The maker of Barbie dolls reported fourth-quarter profit of $1.07 a share, excluding some items, beating the $1 average analyst estimate.

Parexel International Corp. (PRXL US) surged 18 percent, the most since January 2009, to $24.10. The tester of experimental medicines for drugmakers forecast third-quarter earnings of as much as 32 cents a share excluding some items, above the average analyst estimate of 30 cents a share, according to a Bloomberg survey.

RadioShack Corp. (RSH US) plunged 30 percent, the most since at least 1980, to $7.18. The consumer-electronics retailer suspended share repurchases and reported preliminary fourth-quarter earnings that trailed analysts’ estimates. Earnings fell to 11 cents to 13 cents a share last quarter. Analysts projected 37 cents, the average of 19 estimates compiled by Bloomberg. RadioShack cited “underperformance” in the Sprint Nextel Corp. (S US) postpaid wireless business.

Best Buy Co. (BBY US), the world’s largest consumer-electronics retailer, slipped 5.6 percent to $23.95 for the biggest decline in the Standard & Poor’s 500 Index.

Rent-A-Center Inc. (RCII US) slumped 9.1 percent, the most since Aug. 8, to $33.82. The biggest U.S. rent-to-own retailer forecast earnings for 2012 to be no more than $3.20 a share, missing the average analyst estimate of $3.22.

Rex Energy Corp. (REXX US) erased 11 percent to $9.46, the lowest price since August 2010. The oil and gas company with operations in the Illinois and Appalachian basin announced plans for a public offering of 7 million ordinary shares. Additional stock may dilute the value of existing shares.

VeriFone Systems Inc. (PAY US) climbed the most in the Russell 1000 Index, jumping 8.4 percent to $42.70. The largest maker of credit-card terminals is likely to benefit most from MasterCard Inc.’s (MA US) introduction of electronic payment system, JPMorgan Chase & Co. said.

Vertex Pharmaceuticals Inc. (VRTX US) rose 6.4 percent, the most since Dec. 16, to $36.95. The drugmaker’s Kalydeco won approval from the U.S. Food and Drug Administration to treat cystic fibrosis.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.